Antivascular Ultrasound Therapy Extends Survival of Mice with Implanted Melanomas

Overview

Journal Ultrasound Med Biol

Specialty Radiology

Date 2010 Apr 13

PMID 20381952

Citations 26

Authors

Andrew K W Wood

Susan M Schultz

William M-F Lee

Ralph M Bunte

Chandra M Sehgal

Affiliations

Soon will be listed here.

Abstract

The goal of this murine investigation was to evaluate the effect of an antivascular ultrasound treatment on the growth of an implanted melanoma and the consequent survival rate. After the intravenous injection of 0.2 mL ultrasound contrast agent (Definity), therapy (n = 15) was performed on 1-mL tumors for 3 min with low-intensity continuous ultrasound (3 MHz; 2.4 +/- 0.1 W cm(-2) [I(SATA)]); control mice (n = 17) received a sham treatment. Mice were euthanized once the tumor had reached 3 mL, and then survival percentage vs. time curves were plotted. The median survival time (time for tumor to reach 3 mL) for the treated group was 23 d and for the control group was 18 d; the difference was statistically significant (p <or= 0.0001). Antivascular ultrasound therapy reduced the growth rate of an implanted melanoma and increased survival time. The ultrasound therapy provides a further example of tumor vascular disruption, and its future clinical potential should be investigated.

Citing Articles

In vivo high-speed microscopy of microbubbles in the chorioallantoic membrane model.

Anbarafshan R, Pellow C, Kiezun K, Leong H, Goertz D Theranostics. 2024; 14(5):1794-1814.

PMID: 38505609 PMC: 10945333. DOI: 10.7150/thno.91232.

Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.

Nittayacharn P, Abenojar E, Cooley M, Berg F, Counil C, Sojahrood A J Control Release. 2024; 367:135-147.

PMID: 38237687 PMC: 11700473. DOI: 10.1016/j.jconrel.2024.01.028.

Synchronous Intravital Imaging and Cavitation Monitoring of Antivascular Focused Ultrasound in Tumor Microvasculature Using Monodisperse Low Boiling Point Nanodroplets.

Pellow C, Sojahrood A, Zhao X, Kolios M, Exner A, Goertz D ACS Nano. 2023; 18(1):410-427.

PMID: 38147452 PMC: 10786165. DOI: 10.1021/acsnano.3c07711.

Efficient ultrasound-mediated drug delivery to orthotopic liver tumors - Direct comparison of doxorubicin-loaded nanobubbles and microbubbles.

Nittayacharn P, Abenojar E, Cooley M, Berg F, Counil C, Sojahrood A bioRxiv. 2023; .

PMID: 37732235 PMC: 10508722. DOI: 10.1101/2023.09.01.555196.

Theranostics in the vasculature: bioeffects of ultrasound and microbubbles to induce vascular shutdown.

Padilla F, Brenner J, Prada F, Klibanov A Theranostics. 2023; 13(12):4079-4101.

PMID: 37554276 PMC: 10405856. DOI: 10.7150/thno.70372.

References

Susani M, Madersbacher S, Kratzik C, Vingers L, Marberger M . Morphology of tissue destruction induced by focused ultrasound. Eur Urol. 1993; 23 Suppl 1:34-8. DOI: 10.1159/000474677. View

Hande K, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H . The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006; 12(9):2834-40. DOI: 10.1158/1078-0432.CCR-05-2159. View

Maestroni U, Ziveri M, Azzolini N, Dinale F, Ziglioli F, Campaniello G . High Intensity Focused Ultrasound (HIFU): a useful alternative choice in prostate cancer treatment. Preliminary results. Acta Biomed. 2009; 79(3):211-6. View

Beerepoot L, Radema S, Witteveen E, Thomas T, Wheeler C, Kempin S . Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol. 2006; 24(10):1491-8. DOI: 10.1200/JCO.2005.02.7458. View

Denekamp J . Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer. 1982; 45(1):136-9. PMC: 2010961. DOI: 10.1038/bjc.1982.16. View

Chaplin D, Hill S . The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys. 2002; 54(5):1491-6. DOI: 10.1016/s0360-3016(02)03924-x. View

Bunte R, Ansaloni S, Sehgal C, Lee W, Wood A . Histopathological observations of the antivascular effects of physiotherapy ultrasound on a murine neoplasm. Ultrasound Med Biol. 2006; 32(3):453-61. DOI: 10.1016/j.ultrasmedbio.2005.12.005. View

Sehgal C, Cary T, Arger P, Wood A . Delta-projection imaging on contrast-enhanced ultrasound to quantify tumor microvasculature and perfusion. Acad Radiol. 2008; 16(1):71-8. PMC: 2644424. DOI: 10.1016/j.acra.2008.07.013. View

Wood A, Bunte R, Cohen J, Tsai J, Lee W, Sehgal C . The antivascular action of physiotherapy ultrasound on a murine tumor: role of a microbubble contrast agent. Ultrasound Med Biol. 2007; 33(12):1901-10. PMC: 2423191. DOI: 10.1016/j.ultrasmedbio.2007.06.013. View

10.

Denekamp J, Hill S, Hobson B . Vascular occlusion and tumour cell death. Eur J Cancer Clin Oncol. 1983; 19(2):271-5. DOI: 10.1016/0277-5379(83)90426-1. View

11.

Wood A, Bunte R, Price H, Deitz M, Tsai J, Lee W . The disruption of murine tumor neovasculature by low-intensity ultrasound-comparison between 1- and 3-MHz sonication frequencies. Acad Radiol. 2008; 15(9):1133-41. PMC: 2597509. DOI: 10.1016/j.acra.2008.04.012. View

12.

Chabot G, Bissery M, Corbett T, Rutkowski K, Baker L . Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice. Cancer Chemother Pharmacol. 1989; 24(1):15-22. DOI: 10.1007/BF00254099. View

13.

Wood A, Ansaloni S, Ziemer L, Lee W, Feldman M, Sehgal C . The antivascular action of physiotherapy ultrasound on murine tumors. Ultrasound Med Biol. 2005; 31(10):1403-10. PMC: 2442571. DOI: 10.1016/j.ultrasmedbio.2005.06.008. View

14.

Nielsen T, Murata R, Maxwell R, Stodkilde-Jorgensen H, Ostergaard L, Horsman M . Preclinical studies to predict efficacy of vascular changes induced by combretastatin a-4 disodium phosphate in patients. Int J Radiat Oncol Biol Phys. 2008; 70(3):859-66. DOI: 10.1016/j.ijrobp.2007.10.012. View

15.

Salmon B, Siemann D . Characterizing the tumor response to treatment with combretastatin A4 phosphate. Int J Radiat Oncol Biol Phys. 2007; 68(1):211-7. PMC: 1868579. DOI: 10.1016/j.ijrobp.2006.12.051. View

16.

Rustin G, Galbraith S, Anderson H, Stratford M, Folkes L, Sena L . Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003; 21(15):2815-22. DOI: 10.1200/JCO.2003.05.185. View

17.

Tozer G, Kanthou C, Lewis G, Prise V, Vojnovic B, Hill S . Tumour vascular disrupting agents: combating treatment resistance. Br J Radiol. 2008; 81 Spec No 1:S12-20. DOI: 10.1259/bjr/36205483. View

18.

Rubio Briones J, Collado Serra A, Gomez-Ferrer Lozano A, Casanova Ramon-Borja J, Iborra Juan I, Solsona Narbon E . High-intensity focused ultrasound in small renal masses. Adv Urol. 2009; :809845. PMC: 2612759. DOI: 10.1155/2008/809845. View

19.

Rustin G, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S . 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer. 2003; 88(8):1160-7. PMC: 2747563. DOI: 10.1038/sj.bjc.6600885. View

20.

Baguley B . Antivascular therapy of cancer: DMXAA. Lancet Oncol. 2003; 4(3):141-8. DOI: 10.1016/s1470-2045(03)01018-0. View